Literature DB >> 11238060

Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes.

G Strathdee1, K Appleton, M Illand, D W Millan, J Sargent, J Paul, R Brown.   

Abstract

Mounting evidence suggests that aberrant methylation of CpG islands is a major pathway leading to the inactivation of tumor suppressor genes and the development of cancer. Recent studies on colorectal and gastric cancer have defined a CpG island methylator phenotype (CIMP), which involves the targeting of multiple genes by promoter hypermethylation. To determine the role of methylation in ovarian cancer, we have investigated the methylation status of 93 primary ovarian tumors at ten loci using methylation-specific polymerase chain reaction (MSP). Seven of the loci (BRCA1, HIC1, MINT25, MINT31, MLH1, p73 and hTR) were found to be methylated in a significant proportion of the ovarian tumors, and methylation of at least one of these was found in the majority (71%) of samples. Although concurrent methylation of multiple genes was commonly seen, this did not seem to be due to a single CIMP phenotype. Instead the results suggest the presence of at least three groups of tumors, two CIMP-positive groups, each susceptible to methylation of a different subset of genes, and a further group of tumors not susceptible to CpG island methylation, at least at the loci studied.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238060      PMCID: PMC1850352          DOI: 10.1016/S0002-9440(10)64059-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  33 in total

1.  COBRA: a sensitive and quantitative DNA methylation assay.

Authors:  Z Xiong; P W Laird
Journal:  Nucleic Acids Res       Date:  1997-06-15       Impact factor: 16.971

2.  CpG islands in vertebrate genomes.

Authors:  M Gardiner-Garden; M Frommer
Journal:  J Mol Biol       Date:  1987-07-20       Impact factor: 5.469

3.  Rare mutations and no hypermethylation at the CDKN2A locus in epithelial ovarian tumours.

Authors:  Y C Shih; J Kerr; J Liu; T Hurst; S K Khoo; B Ward; B Wainwright; G Chenevix-Trench
Journal:  Int J Cancer       Date:  1997-03-04       Impact factor: 7.396

4.  p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors.

Authors:  K Milde-Langosch; E Ocon; G Becker; T Löning
Journal:  Int J Cancer       Date:  1998-02-20       Impact factor: 7.396

5.  Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene.

Authors:  T Sakai; J Toguchida; N Ohtani; D W Yandell; J M Rapaport; T P Dryja
Journal:  Am J Hum Genet       Date:  1991-05       Impact factor: 11.025

Review 6.  The relationship of DNA methylation to cancer.

Authors:  A P Bird
Journal:  Cancer Surv       Date:  1996

7.  Methylation of the BRCA1 gene in sporadic breast cancer.

Authors:  A Dobrovic; D Simpfendorfer
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

8.  Hypermethylation at a chromosome 17 "hot spot" is a common event in ovarian cancer.

Authors:  M Pieretti; D E Powell; H H Gallion; P S Conway; E A Case; M S Turker
Journal:  Hum Pathol       Date:  1995-04       Impact factor: 3.466

9.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.

Authors:  J G Herman; A Merlo; L Mao; R G Lapidus; J P Issa; N E Davidson; D Sidransky; S B Baylin
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

10.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more
  60 in total

Review 1.  Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America.

Authors:  Megan A Murphy; Nicolas Wentzensen
Journal:  Int J Cancer       Date:  2011-04-04       Impact factor: 7.396

2.  Methylation profile in benign, borderline and malignant ovarian tumors.

Authors:  K F Tam; V W S Liu; S S Liu; P C K Tsang; A N Y Cheung; A M W Yip; H Y S Ngan
Journal:  J Cancer Res Clin Oncol       Date:  2006-12-20       Impact factor: 4.553

Review 3.  Ovarian cancer: linking genomics to new target discovery and molecular markers--the way ahead.

Authors:  Bryan T Hennessy; Mandi Murph; Meera Nanjundan; Mark Carey; Nelly Auersperg; Jonas Almeida; Kevin R Coombes; Jinsong Liu; Yiling Lu; Joe W Gray; Gordon B Mills
Journal:  Adv Exp Med Biol       Date:  2008       Impact factor: 2.622

Review 4.  Translational application of epigenetic alterations: ovarian cancer as a model.

Authors:  Marie E Maradeo; Paul Cairns
Journal:  FEBS Lett       Date:  2011-03-12       Impact factor: 4.124

5.  Differential methylation profile of ovarian cancer in tissues and plasma.

Authors:  Anatoliy Melnikov; Denise Scholtens; Andrew Godwin; Victor Levenson
Journal:  J Mol Diagn       Date:  2008-12-12       Impact factor: 5.568

Review 6.  Nutrition in early life, and risk of cancer and metabolic disease: alternative endings in an epigenetic tale?

Authors:  Graham C Burdge; Karen A Lillycrop; Alan A Jackson
Journal:  Br J Nutr       Date:  2008-12-12       Impact factor: 3.718

7.  53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.

Authors:  Kathryn P Pennington; Anneka Wickramanayake; Barbara M Norquist; Christopher C Pennil; Rochelle L Garcia; Kathy J Agnew; Toshiyasu Taniguchi; Piri Welcsh; Elizabeth M Swisher
Journal:  Gynecol Oncol       Date:  2012-12-12       Impact factor: 5.482

Review 8.  Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology.

Authors:  Tuya Pal; Jenny Permuth-Wey; Ambuj Kumar; Thomas A Sellers
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

9.  Array-based DNA methylation profiling for breast cancer subtype discrimination.

Authors:  Ilse Van der Auwera; Wayne Yu; Liping Suo; Leander Van Neste; Peter van Dam; Eric A Van Marck; Patrick Pauwels; Peter B Vermeulen; Luc Y Dirix; Steven J Van Laere
Journal:  PLoS One       Date:  2010-09-07       Impact factor: 3.240

10.  Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.

Authors:  Elizabeth M Swisher; Rachel M Gonzalez; Toshiyasu Taniguchi; Rochelle L Garcia; Tom Walsh; Barbara A Goff; Piri Welcsh
Journal:  Mol Cancer       Date:  2009-07-14       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.